Last reviewed · How we verify
FAAH Inhibitor Trial for Adults With Tourette Syndrome
The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
Details
| Lead sponsor | Yale University |
|---|---|
| Phase | Phase 1 |
| Status | TERMINATED |
| Enrolment | 5 |
| Start date | 2014-05 |
| Completion | 2017-03 |
Conditions
- Tourette Syndrome
Interventions
- PF-04457845
- Placebo
Primary outcomes
- Improvement in Tic Severity — Evaluated each time subject seen over approximately 12 weeks
Yale Global Tic Severity Scale (Total Tic Score)
Countries
United States